Versartis is a clinical development spin-out from Amunix which has human growth hormone-XTEN in Phase I clinical trials. For more information, see www.versartis.com.
Amunix has a research collaboration with Biogen Idec on XTEN–derivatives of blood factors (FVIIa, FVIII and FIX) with improved therapeutic properties. For more information, see the press release.
Diartis is a clinical development spin-out which has Exenatide-XTEN in Phase I clinical trials. For more information, see www.diartispharma.com.
